Zeltiq Aesthetics Inc 4

4 · Zeltiq Aesthetics Inc · Filed Apr 28, 2017

Form 4

Period: 2017-04-28

Director

Transactions

Other
Common Stock
2017-04-28−11,985→ 0 total
Other
Stock Options (Right to Buy)
2017-04-28−10,645→ 0 total
Exercise: $6.34Exp: 2023-06-18→ Common Stock (10,645 underlying)
Other
Stock Options (Right to Buy)
2017-04-28−40,871→ 0 total
Exercise: $10.21Exp: 2021-07-28→ Common Stock (40,871 underlying)
Other
Stock Options (Right to Buy)
2017-04-28−30,000→ 0 total
Exercise: $17.48Exp: 2024-05-29→ Common Stock (30,000 underlying)
Other
Stock Options (Right to Buy)
2017-04-28−1,391→ 0 total
Exercise: $5.06Exp: 2022-06-14→ Common Stock (1,391 underlying)

Footnotes (3)

[F1]Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger").
[F2]Pursuant to the terms of the Merger Agreement, out of the total of 11,985 shares held by the Reporting Person, (i) 10,952 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes (the "Merger Consideration"), and (ii) 1,033 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted stock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as adjusted based on an exchange ratio.
[F3]This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option.

Documents

1 file